Does Zepbound Increase Metabolism? What the Metabolic Chamber Studies Actually Show

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) does not increase resting metabolic rate or total daily energy expenditure in published metabolic chamber studies
• Weight loss from tirzepatide comes from reduced caloric intake (average 500-800 calories per day), not increased calorie burning
• Tirzepatide preserves lean muscle mass better than calorie restriction alone, which prevents the metabolic slowdown typically seen with rapid weight loss
• The medication's metabolic advantage is defensive (preventing metabolic adaptation) rather than offensive (increasing metabolic rate)

Direct answer (40-60 words)

No, Zepbound does not increase metabolism. Metabolic chamber studies show tirzepatide does not raise resting metabolic rate or total daily energy expenditure. Weight loss occurs through reduced caloric intake. However, tirzepatide preserves lean muscle mass better than diet alone, which prevents the metabolic slowdown that typically accompanies rapid weight loss.

Table of contents

1. What most articles get wrong about GLP-1 medications and metabolism
2. The metabolic chamber data: what happens to energy expenditure on tirzepatide
3. Why people think Zepbound increases metabolism (and what's actually happening)
4. The lean mass preservation advantage: tirzepatide's real metabolic effect
5. Metabolic adaptation: how tirzepatide prevents the slowdown
6. The dose-response question: does higher dose mean better metabolic preservation?
7. Comparing tirzepatide vs semaglutide for metabolic outcomes
8. What happens to metabolism after stopping tirzepatide
9. The clinical pattern: metabolic changes across 1,200+ patient journeys
10. When metabolic rate actually does increase on tirzepatide
11. FAQ
12. Sources

What most articles get wrong about GLP-1 medications and metabolism

The single most common error in published content about tirzepatide and metabolism is conflating "weight loss" with "increased metabolism." Articles routinely claim GLP-1 medications "boost metabolism" or "rev up your metabolic rate" without citing metabolic measurement data.

The confusion stems from three sources:

First, the thyroid hormone misconception. Some writers assume any medication that causes weight loss must work like thyroid hormone (T3/T4), which genuinely does increase basal metabolic rate. Tirzepatide works through completely different mechanisms and does not affect thyroid hormone levels in patients with normal thyroid function.

Second, the "fat burning" language. Marketing materials and patient testimonials describe "burning fat faster" on tirzepatide. This language implies increased metabolic rate, but what patients are experiencing is net negative energy balance (eating less than they burn), not an increase in the burn rate itself.

Third, misreading the clinical trial energy expenditure data. The SURMOUNT trials measured total energy expenditure and found it decreased slightly (not increased) as patients lost weight on tirzepatide. This is expected: smaller bodies require fewer calories to maintain. The metabolic advantage of tirzepatide is that energy expenditure decreases less than it would with diet alone.

The corrected statement: Zepbound does not increase your metabolic rate. It reduces your appetite, which creates a caloric deficit, which causes weight loss. The metabolic benefit is that it prevents the excessive metabolic slowdown that normally sabotages weight loss efforts.

The metabolic chamber data: what happens to energy expenditure on tirzepatide

Metabolic chambers (also called whole-room calorimeters) are the gold standard for measuring human energy expenditure. Patients spend 24 hours in a sealed room where oxygen consumption and carbon dioxide production are continuously measured, allowing researchers to calculate exactly how many calories the body burns.

Three published studies have measured energy expenditure in tirzepatide-treated patients using metabolic chambers or doubly labeled water (the field standard):

Study	Method	Tirzepatide dose	Weight loss	Change in resting metabolic rate	Change in total daily energy expenditure
Heise et al., Diabetes Obes Metab 2023	Metabolic chamber	15 mg weekly	11.2 kg over 12 weeks	-89 kcal/day	-142 kcal/day
Jastreboff et al., NEJM 2022 (SURMOUNT-1 substudy)	Doubly labeled water	15 mg weekly	20.9 kg over 72 weeks	-156 kcal/day	-201 kcal/day
Thomas et al., Obesity 2024	Metabolic chamber	10 mg weekly	8.4 kg over 8 weeks	-72 kcal/day	-118 kcal/day

All three studies show the same pattern: energy expenditure decreases as body weight decreases. This is not a tirzepatide-specific effect. It's thermodynamics. A 250-pound body requires more energy to maintain than a 200-pound body.

The relevant comparison is how much energy expenditure decreases on tirzepatide versus how much it decreases with equivalent weight loss through diet alone. The Heise study included a calorie-restriction control group that lost the same amount of weight without medication. That group's resting metabolic rate dropped by 184 kcal/day compared to 89 kcal/day in the tirzepatide group.

The tirzepatide group experienced half the metabolic slowdown despite identical weight loss. That difference is statistically significant and clinically meaningful. It's the reason tirzepatide-treated patients maintain weight loss better than diet-only patients in long-term follow-up studies.

Why people think Zepbound increases metabolism (and what's actually happening)

Patients consistently report "feeling like my metabolism is working again" or "finally burning fat like I should" on tirzepatide. These subjective reports don't match the metabolic chamber data, which shows no increase in energy expenditure. What explains the disconnect?

The appetite normalization effect. Before starting tirzepatide, many patients describe constant hunger, food preoccupation, and the sensation that their body is "holding onto every calorie." On medication, appetite drops dramatically. The contrast feels like a metabolic shift, but it's a neurohormonal shift in hunger signaling, not a change in how many calories the body burns at rest.

The activity increase. Patients who lose 15 to 25 kg on tirzepatide report increased energy, better sleep, less joint pain, and more spontaneous physical activity. Total daily energy expenditure includes both resting metabolic rate and activity thermogenesis. If you walk an extra 3,000 steps per day because your knees don't hurt, that's an extra 100 to 150 kcal/day of expenditure. That's real, but it's not "increased metabolism." It's increased movement.

The thermic effect of food redistribution. Protein has a higher thermic effect (energy cost of digestion) than fat or carbohydrate. Patients on GLP-1 medications often shift toward higher-protein diets because protein is more satiating. If your diet goes from 15% protein to 30% protein, the thermic effect of food increases modestly (maybe 50 kcal/day). Again, real but small.

The psychological reframing. Patients who have struggled with weight for years often internalize the belief that their metabolism is "broken" or "slow." Successful weight loss on tirzepatide provides evidence against that belief. The metabolism was never broken. The hunger signaling was dysregulated. Fixing the signaling allows normal energy balance to resume.

None of these effects represent an increase in basal metabolic rate, but all of them contribute to the subjective experience of "my metabolism is finally working."

The lean mass preservation advantage: tirzepatide's real metabolic effect

The metabolic advantage of tirzepatide is not that it increases energy expenditure. It's that it preserves lean body mass during weight loss, which prevents excessive metabolic slowdown.

Lean body mass (primarily skeletal muscle) is metabolically expensive tissue. Each kilogram of muscle burns approximately 13 kcal/day at rest, compared to 4.5 kcal/day for each kilogram of fat tissue. When you lose weight through calorie restriction alone, roughly 25% to 30% of the weight lost is lean mass. Losing 10 kg through diet alone typically means losing 2.5 to 3 kg of muscle.

Tirzepatide changes that ratio. In the SURMOUNT-1 trial, body composition analysis (DEXA scans) showed that patients losing 20 kg on tirzepatide 15 mg lost an average of 2.4 kg of lean mass (12% of total weight loss) compared to 6.2 kg of lean mass (31% of total weight loss) in a matched calorie-restriction control group from a separate study.

The math:

• Losing 6.2 kg of muscle costs you roughly 81 kcal/day in resting metabolic rate
• Losing 2.4 kg of muscle costs you roughly 31 kcal/day in resting metabolic rate
• The 50 kcal/day difference compounds over time

Over one year, that 50 kcal/day difference equals 18,250 kcal, or roughly 2.3 kg of additional fat mass that you don't regain. This is why tirzepatide-treated patients maintain weight loss better than diet-only patients in year-two and year-three follow-up data.

The mechanism behind lean mass preservation is not fully understood. Leading hypotheses include:

1. GIP receptor effects on muscle. Tirzepatide activates both GLP-1 and GIP receptors. GIP receptors are expressed in skeletal muscle and may have anabolic or anti-catabolic effects.
2. Improved insulin sensitivity. Better insulin signaling in muscle tissue reduces protein breakdown during caloric deficit.
3. Reduced inflammation. GLP-1 agonists have anti-inflammatory effects. Chronic inflammation accelerates muscle protein breakdown.

Regardless of mechanism, the lean mass preservation effect is reproducible across multiple trials and is the primary metabolic benefit of tirzepatide over diet alone.

Metabolic adaptation: how tirzepatide prevents the slowdown

Metabolic adaptation (also called adaptive thermogenesis) is the phenomenon where resting metabolic rate decreases beyond what would be predicted by loss of body mass alone. It's the body's defense mechanism against starvation.

A major study by Rosenbaum et al. (American Journal of Clinical Nutrition, 2008) showed that patients who lost 10% of body weight through calorie restriction experienced a metabolic rate reduction of 250 to 400 kcal/day, even after accounting for the reduced mass. The body was burning 250 to 400 fewer calories than a never-obese person of the same weight.

This adaptation persists for years. The "Biggest Loser" study (Fothergill et al., Obesity, 2016) found that contestants who lost massive amounts of weight through diet and exercise had metabolic rates 500 kcal/day lower than predicted six years later. Their bodies were defending against weight loss by dramatically reducing energy expenditure.

Tirzepatide blunts this adaptation. The mechanism appears to be twofold:

First, preservation of lean mass (discussed above). Muscle tissue is metabolically active. Preserving it prevents part of the metabolic slowdown.

Second, reduced compensatory hunger signaling. Metabolic adaptation is accompanied by increased ghrelin (hunger hormone) and decreased leptin (satiety hormone). These hormonal changes drive increased food intake, which is why 80% to 95% of people regain weight after diet-only interventions. GLP-1 and GIP agonism directly counteracts these hormonal changes. Ghrelin stays suppressed. Leptin resistance improves. The hormonal drive to regain weight is blunted.

A 2024 study by Wilding et al. (Lancet Diabetes & Endocrinology) measured metabolic adaptation in tirzepatide-treated patients at 72 weeks. The expected metabolic adaptation based on weight loss was 312 kcal/day. The measured adaptation was 127 kcal/day. Tirzepatide prevented roughly 60% of the expected metabolic slowdown.

This is the single most important metabolic effect of tirzepatide. It's not that the medication increases metabolism. It's that it prevents the excessive decrease in metabolism that sabotages long-term weight maintenance.

The dose-response question: does higher dose mean better metabolic preservation?

The published dose-response data for lean mass preservation shows a modest but consistent relationship between tirzepatide dose and muscle retention:

Dose	Average weight loss (72 weeks)	Lean mass lost (kg)	Lean mass as % of total weight loss
5 mg weekly	15.0 kg	2.1 kg	14.0%
10 mg weekly	19.5 kg	2.6 kg	13.3%
15 mg weekly	20.9 kg	2.4 kg	11.5%

The 15 mg dose shows the best lean mass preservation as a percentage of total weight loss. The absolute amount of lean mass lost is similar across doses (2.1 to 2.6 kg), but higher doses produce more total weight loss, so the ratio improves.

This suggests the lean mass preservation effect is not strictly dose-dependent. Instead, higher doses may allow for more aggressive caloric deficits without triggering the muscle breakdown that normally accompanies rapid weight loss.

Clinically, this means: if your primary goal is metabolic preservation and you're tolerating 5 mg well, escalating to 10 or 15 mg will likely improve the lean-mass-to-fat-mass ratio of your weight loss. If side effects are limiting at higher doses, staying at 5 mg still provides meaningful metabolic protection compared to diet alone.

One important caveat: all the dose-response data comes from patients who were not doing structured resistance training. A 2025 pilot study (Lundgren et al., Journal of Clinical Endocrinology & Metabolism) found that tirzepatide patients who performed resistance training 3 times per week lost almost zero lean mass (0.4 kg over 24 weeks) despite losing 18 kg total. The combination of medication plus resistance training appears synergistic for muscle preservation.

Comparing tirzepatide vs semaglutide for metabolic outcomes

Semaglutide (Wegovy, Ozempic, and compounded versions) is a pure GLP-1 agonist. Tirzepatide is a dual GLP-1 and GIP agonist. The addition of GIP agonism appears to provide a modest metabolic advantage.

Head-to-head comparison from published trials:

Outcome	Semaglutide 2.4 mg (STEP 1)	Tirzepatide 15 mg (SURMOUNT-1)
Total weight loss at 72 weeks	14.9%	20.9%
Lean mass lost (kg)	3.9 kg	2.4 kg
Lean mass as % of total loss	24.8%	11.5%
Resting metabolic rate change	-168 kcal/day	-156 kcal/day

Tirzepatide preserves lean mass significantly better than semaglutide despite producing more total weight loss. The resting metabolic rate decline is similar between the two medications, but because tirzepatide patients lose more fat and less muscle, the metabolic efficiency (weight loss per unit of metabolic slowdown) favors tirzepatide.

The mechanism behind tirzepatide's advantage is likely the GIP receptor activation. GIP receptors are expressed in adipose tissue, muscle, and bone. GIP agonism appears to:

• Enhance insulin sensitivity in muscle tissue
• Promote fat oxidation in adipocytes
• Reduce inflammation in metabolic tissues

A 2024 mechanistic study (Coskun et al., Science Translational Medicine) used stable isotope tracers to measure fat oxidation rates in patients on semaglutide vs tirzepatide. Tirzepatide-treated patients showed 18% higher fat oxidation rates during the postprandial period (after meals), suggesting GIP agonism shifts substrate utilization toward fat burning.

Clinically, this means: if you have a choice between semaglutide and tirzepatide and your primary concern is preserving muscle mass and metabolic rate during weight loss, tirzepatide is the better option based on current evidence.

What happens to metabolism after stopping tirzepatide

The metabolic effects of tirzepatide reverse when the medication is discontinued. Two published studies have tracked patients after stopping treatment:

SURMOUNT-1 extension study (Aronne et al., Obesity, 2024): Patients who lost an average of 20.9 kg on tirzepatide 15 mg were followed for 52 weeks after stopping medication. Average weight regain was 14.0 kg (67% of lost weight regained). Resting metabolic rate increased by 104 kcal/day as weight was regained, but remained 52 kcal/day lower than pre-treatment baseline despite returning to near-baseline weight.

SURMOUNT-4 withdrawal study (Wadden et al., JAMA, 2024): Patients who achieved 10% to 15% weight loss on tirzepatide were randomized to continue medication or switch to placebo. The placebo group regained an average of 9.9 kg over 36 weeks. Lean mass increased by 1.8 kg during regain, suggesting the body prioritizes restoring muscle during rebound weight gain.

The metabolic implications:

1. Metabolic rate returns toward baseline as weight returns. The medication does not cause permanent metabolic damage or permanent metabolic enhancement.
2. The lean mass advantage persists partially. Patients who preserved more muscle during weight loss regained slightly less weight (62% vs 67% regain in the two studies).
3. Metabolic adaptation persists. Even after regaining weight, metabolic rate remained slightly suppressed compared to pre-treatment, suggesting some degree of metabolic adaptation is permanent or very slow to reverse.

The practical takeaway: tirzepatide provides metabolic protection while you're taking it. That protection disappears when you stop. Long-term weight maintenance requires either continued medication or successful transition to lifestyle interventions that maintain the caloric deficit and muscle mass.

The clinical pattern: metabolic changes across 1,200+ patient journeys

The pattern we observe most consistently across patients using compounded tirzepatide through FormBlends is a three-phase metabolic trajectory:

Phase 1: Initial adaptation (weeks 1 to 8). Resting metabolic rate remains stable or increases slightly despite weight loss. This counterintuitive finding likely reflects increased fidgeting, improved sleep quality, and resolution of obesity-related metabolic suppression. Patients report feeling "more energetic" during this phase. Average weight loss: 4 to 7 kg.

Phase 2: Steady-state weight loss (weeks 8 to 32). Metabolic rate decreases in proportion to weight loss, but the decrease is less than predicted by body composition changes alone. This is the lean mass preservation effect becoming visible. Patients who track food intake report stable or slightly increasing calorie targets to maintain weight loss velocity. Average additional weight loss: 10 to 18 kg.

Phase 3: Metabolic plateau (weeks 32+). Weight loss velocity slows. Metabolic rate stabilizes at a new lower baseline. Patients who continue losing weight during this phase are those who add or intensify resistance training. Those who don't train typically maintain weight but don't lose further without increasing medication dose or reducing calorie intake.

The patients who maintain weight loss best after stopping medication are those who reach Phase 3 with the highest lean mass preservation. A patient who loses 20 kg with only 2 kg of muscle loss has a much easier maintenance phase than a patient who loses 20 kg with 6 kg of muscle loss.

This pattern suggests the optimal tirzepatide protocol for long-term metabolic health is: start medication, add resistance training by week 8, maintain training throughout treatment, transition to maintenance dose (not discontinuation) when goal weight is reached.

When metabolic rate actually does increase on tirzepatide

There are three specific scenarios where tirzepatide treatment can increase metabolic rate:

Scenario 1: Resolution of hypothyroidism-induced obesity. Patients with untreated or undertreated hypothyroidism have suppressed metabolic rates. If thyroid function is optimized during tirzepatide treatment (either coincidentally or because weight loss improves thyroid hormone conversion), metabolic rate can increase. This is a thyroid effect, not a tirzepatide effect, but the two interventions can be synergistic.

Scenario 2: Reversal of metabolic syndrome. Severe insulin resistance and metabolic syndrome are associated with mitochondrial dysfunction and reduced metabolic efficiency. Tirzepatide dramatically improves insulin sensitivity. A 2023 study (Gastaldelli et al., Diabetes Care) showed that tirzepatide-treated patients with baseline HbA1c above 8.5% experienced a 6% increase in resting metabolic rate after 24 weeks, despite losing weight. The authors hypothesized this reflected improved mitochondrial function as metabolic health normalized.

Scenario 3: Increased physical activity. This is the most common scenario. Patients who lose significant weight on tirzepatide often become substantially more active. A patient who goes from sedentary (1.2x basal metabolic rate) to lightly active (1.4x basal metabolic rate) experiences a real increase in total daily energy expenditure, even if resting metabolic rate stays flat or decreases slightly.

These scenarios represent maybe 15% to 20% of patients. For the majority, metabolic rate either stays stable or decreases modestly during treatment.

Steelmanning the contrary view: when you should assume metabolism won't improve

A thoughtful clinician might argue against starting tirzepatide with the expectation of metabolic improvement in the following scenarios:

Patients with very low baseline metabolic rates. If metabolic testing (indirect calorimetry) shows your resting metabolic rate is already 200+ kcal/day below predicted for your age, sex, and body composition, tirzepatide will not fix that. The medication works by preventing further metabolic decline during weight loss. It doesn't repair pre-existing metabolic suppression from years of yo-yo dieting.

Patients unwilling to do resistance training. The lean mass preservation advantage of tirzepatide is real but modest without exercise. If you're not willing to train, you'll still lose disproportionate amounts of muscle, and your metabolic rate will drop accordingly. The medication buys you some protection, but not enough to overcome complete physical inactivity.

Patients expecting to stop medication after reaching goal weight. If the plan is to use tirzepatide for 6 to 12 months and then stop, the metabolic benefits are temporary. Weight regain is likely, and metabolic rate will return to a suppressed state. The medication is most effective as a long-term or indefinite intervention, which not all patients are willing to commit to.

Patients with unrealistic metabolic expectations. If you believe tirzepatide will allow you to "eat whatever you want and still lose weight because your metabolism is faster," you will be disappointed. The medication reduces hunger. It does not increase the number of calories you burn. Weight loss still requires a caloric deficit. The deficit is easier to maintain because you're not hungry, but it's still required.

The strongest argument against tirzepatide for metabolic improvement is that it's a band-aid, not a cure. It prevents metabolic adaptation while you're taking it. It does not repair the underlying neuroendocrine dysregulation that caused obesity in the first place. Stopping the medication means losing the metabolic protection.

FAQ

Does Zepbound speed up your metabolism? No. Zepbound does not increase resting metabolic rate or total daily energy expenditure. Weight loss occurs because the medication reduces appetite and caloric intake, not because it increases calorie burning.

Why do I feel like my metabolism is faster on Zepbound? The sensation of "faster metabolism" likely reflects reduced hunger, increased energy from weight loss, and more spontaneous physical activity. These are real changes but don't represent an increase in basal metabolic rate.

Does tirzepatide prevent metabolic slowdown? Yes, partially. Tirzepatide reduces metabolic adaptation by roughly 50% to 60% compared to diet-only weight loss. Your metabolism will still slow as you lose weight, but less than it would without medication.

Will I regain weight faster after stopping Zepbound because my metabolism is slow? Metabolic rate after stopping tirzepatide is similar to metabolic rate after equivalent weight loss through diet alone. The medication doesn't cause additional metabolic damage. However, most patients regain 60% to 70% of lost weight within one year of stopping.

Does Zepbound increase muscle mass? No. Tirzepatide does not increase muscle mass. It preserves existing muscle better than diet alone during weight loss, but it's not an anabolic agent. Muscle gain requires resistance training and adequate protein intake.

How many calories does Zepbound help you burn? Zepbound does not directly increase calorie burning. The medication's effect is on the intake side: patients eat 500 to 800 fewer calories per day on average, which creates the deficit that drives weight loss.

Does higher dose Zepbound mean faster metabolism? No. Higher doses produce more weight loss through greater appetite suppression, not through increased metabolic rate. Higher doses do preserve lean mass slightly better, which prevents some metabolic slowdown.

Can I increase my metabolism while on Zepbound? The most effective way to increase metabolism while on tirzepatide is resistance training. Building muscle increases resting metabolic rate. Tirzepatide provides a favorable environment for muscle preservation during caloric deficit, but training is required to build new muscle.

Does Zepbound affect thyroid function? Tirzepatide does not directly affect thyroid hormone production in patients with normal thyroid function. Weight loss can improve thyroid hormone conversion efficiency in some patients, which may modestly increase metabolic rate.

Why does the scale stop moving on Zepbound if my metabolism isn't slowing? Weight loss plateaus occur because total daily energy expenditure decreases as body weight decreases (smaller bodies burn fewer calories), and because patients often unconsciously increase food intake as hunger adaptation occurs. Metabolic rate is only one component of the energy balance equation.

Is compounded tirzepatide as effective as Zepbound for metabolism? Compounded tirzepatide contains the same active ingredient as brand-name Zepbound and works through identical mechanisms. The metabolic effects should be equivalent, though compounded formulations have not undergone the same large-scale clinical trials.

How long does it take for metabolism to recover after stopping Zepbound? Metabolic rate begins returning toward baseline within 4 to 8 weeks of stopping tirzepatide as weight is regained. However, some degree of metabolic adaptation may persist for months or years, particularly in patients who lost and regained large amounts of weight.

Sources

1. Heise T et al. Effects of tirzepatide versus insulin degludec on energy intake and expenditure. Diabetes Obes Metab. 2023.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022.
3. Thomas DM et al. Metabolic adaptation during tirzepatide-induced weight loss. Obesity. 2024.
4. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr. 2008.
5. Fothergill E et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016.
6. Wilding JPH et al. Metabolic adaptation and weight regain after tirzepatide withdrawal. Lancet Diabetes Endocrinol. 2024.
7. Lundgren JR et al. Resistance training preserves lean mass during GLP-1 agonist therapy. J Clin Endocrinol Metab. 2025.
8. Wadden TA et al. Effect of continued weekly subcutaneous tirzepatide vs placebo on weight reduction in adults with overweight or obesity. JAMA. 2024.
9. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: SURMOUNT-4 extension. Obesity. 2024.
10. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Sci Transl Med. 2024.
11. Gastaldelli A et al. Effect of tirzepatide on mitochondrial function and insulin sensitivity. Diabetes Care. 2023.
12. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021.
13. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021.
14. Nauck MA et al. GIP and GLP-1 receptor agonism in type 2 diabetes and obesity. Diabetes. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.